Nurix Therapeutics, Inc. NRIX AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value

AFS and Trading Securities - Unrealized Loss Position (<12 Months) Fair Value at other companies

Nuvation BioNUVB

——

Ionis PharmaceuticalsIONS

——

Revenue$6.3M-66.1%

Operating income-$92.5M-47.1%

Net income-$87.2M-54.7%

EPS (diluted)-$0.79-17.9%

Cash & equivalents$72.2M-6.1%

Total debt$58.7M+120%

Total equity$480.9M0.0%

Total assets$636.1M+3.4%

Operating cash flow-$71.9M-17.7%

CapEx$1.0M-70.0%

Free cash flow-$73.0M-13.0%

Market cap$1.95B+40.1%

Enterprise value$1.94B+45.1%

P/S27.2×+2.5×

Operating margin-439.3%+35.3pp

Net margin-411.4%+52.7pp

FCF margin-378.7%+24.1pp

Return on equity-61.4%-2.5pp

Debt / equity0.1×+0.1×

Current ratio6×-0.3×

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPositionLessThan12Months.

The official record: Nurix Therapeutics, Inc.’s 10-Q, filed April 8, 2026, on SEC EDGAR. View the filing →

Connect your AI assistant and compare it to peers, right in your chat.

What is Nurix Therapeutics, Inc.'s AFS and trading securities - unrealized loss position (<12 months) fair value?: Nurix Therapeutics, Inc. (NRIX) reported AFS and trading securities - unrealized loss position (<12 months) fair value of $151.57M in Q4 2025.
How has Nurix Therapeutics, Inc.'s AFS and trading securities - unrealized loss position (<12 months) fair value changed year-over-year?: Nurix Therapeutics, Inc.'s AFS and trading securities - unrealized loss position (<12 months) fair value increased by 68.5% year-over-year, from $89.95M to $151.57M.